Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults

Exclusion Criteria

• •Patients with type 1 diabetes or type 2 diabetes with a clear diagnosis;
• •Fasting intravenous blood glucose ≥7 mmol/L or 75g during screening. Oral glucose tolerance test (OGTT) two hours after glucose load;
• •Fasting venous blood glucose \<2.8 mmol/L at screening, and/or those with a history of hypoglycemia;
• •Those who complained of a weight change of \>5% within 3 months before screening;
• •Have used weight loss drugs or hypoglycemic drugs that may affect body weight within 4 weeks before screening;
• •Drugs used within 4 weeks before screening that may cause significant weight gain: including systemic glucocorticoid therapy (lasting more than 1 week); tricyclic antidepressants; antipsychotic or antidepressant drugs; may interfere with blood sugar regulation Functional medicine; all proprietary Chinese medicines and Chinese herbal medicines;
• •Those who have a clear history of malignant tumors,
• •People with Cushing's syndrome, hypothyroidism, polycystic ovary disease or other genetic endocrine diseases or medical history;
• •Those who have a history of bariatric surgery;
• •Have a history of multiple endocrine tumors or a family history; have a history of medullary thyroid carcinoma or other tumors, a family history;
• •History of acute and chronic pancreatitis;
• •Moderate to severe gastrointestinal diseases with additional gastrointestinal motility disorders or obstructive enteropathy;
• •Have a clear history of mental illness